Patrick is a Portfolio Manager for aMoon Edge, where he helps to oversee the fund’s public healthcare investments and also leads private therapeutics investments for aMoon Growth. Prior to joining aMoon in August of 2024, Patrick was a Managing Director and Head of Research at Aquilo Capital Management, a biotechnology-dedicated investment fund focused primarily on small- and mid-cap public therapeutics companies, with a lens towards deep fundamental analysis and value-based investment principles. He has always believed strongly in the positive impact that novel drug development can have for society and is honored to contribute to this ecosystem of amazing scientists and entrepreneurs.
Patrick began his career as a bench scientist in drug development, with a spectrum of roles in discovery and early development for novel biologic and small molecule drugs. This experience includes protein engineering and cell line development for monoclonal antibodies at Xoma, target validation and protein biochemistry for kinase inhibitors at Exelixis, and platform development for expression of antibody-drug conjugates and bispecific antibodies at Sutro Biopharma. Since 2018, he has also been the chair of the Business Development and Finance Committee for ISCT, the International Society for Cellular Therapy, leading a team of biopharmaceutical senior executives with initiatives to connect the investment and cell therapy product development communities.
Patrick received his MBA from UC Berkeley’s Haas School of Business and his Bachelor of Science degree in Chemical Engineering from UCLA, with a specialization in biomedical applications.
